Category: District of Delaware
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.
-
Samsung argues non-infringement or breach of (F)RAND obligations in latest Netlist bout
The Korean company’s District of Delaware complaint follows its targeting in a Netlist infringement action filed on the same day that the patent-in-suit was issued.
-
Micron files declaratory judgment action on same day as patent grant in expansion of chipmakers’ fight with Netlist
The dispute over JEDEC-compliant memory technologies continues with a newly issued patent in the mix.
-
Moderna appeals to save $1.3 billion patent dispute payout, asserts U.S. government-contractor immunity
Moderna has alleged that a district court’s conclusions in a case against Arbutus are “deeply flawed” and that the U.S. Congress created Section 1498 specifically to shield government contractors from liability for government-authorized patent use in fulfilling a government procurement contract.
-
CAT opens new fronts in Doosan dispute with USITC, District of Delaware complaints
The latest filings come in response to Doosan Bobcat’s previous infringement actions in the U.S. and Europe.
-
Federal Circuit says owners of patents subject to exclusive license still have standing to sue where terms don’t render rights “illusory”
A.L.M. and Ergon granted wide-ranging rights to an exclusive licensee – but retained the right to sue third-party infringers.
-
Nvidia, Western Digital among defendants as vertical chip designer MonolithIC 3D expands multi-district litigation campaign
After filing several U.S. infringement suits in recent months, MonolithIC 3D has just fired off another salvo involving a new set of semiconductor design patents.
-
10x settles with Curio, immediately goes on to sue Element Biosciences over next-generation sequencing patents
In the next-generation sequencing space, 10x Genomics has settled its litigation with Curio Biosciences, just before filing a new patent infringement lawsuit against Element Biosciences in Delaware.
-
FedEx can fight another day in Qualcomm dispute, as Federal Circuit considers IPR real-parties-in-interest
The USPTO withdrew its initial defense of the PTAB’s refusal of FedEx’s arguments around real parties in interest.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.